| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MRNA | Common Stock | Options Exercise | $39.6K | +40K | +0.74% | $0.99* | 5.45M | Sep 21, 2022 | Direct | F1 |
| transaction | MRNA | Common Stock | Sale | -$250K | -1.99K | -0.04% | $126.16 | 5.45M | Sep 21, 2022 | Direct | F1, F2 |
| transaction | MRNA | Common Stock | Sale | -$630K | -4.94K | -0.09% | $127.53 | 5.45M | Sep 21, 2022 | Direct | F1, F3 |
| transaction | MRNA | Common Stock | Sale | -$1.32M | -10.3K | -0.19% | $128.80 | 5.43M | Sep 21, 2022 | Direct | F1, F4 |
| transaction | MRNA | Common Stock | Sale | -$2.35M | -18.1K | -0.33% | $129.50 | 5.42M | Sep 21, 2022 | Direct | F1, F5 |
| transaction | MRNA | Common Stock | Sale | -$427K | -3.27K | -0.06% | $130.50 | 5.41M | Sep 21, 2022 | Direct | F1, F6 |
| transaction | MRNA | Common Stock | Sale | -$184K | -1.4K | -0.03% | $131.44 | 5.41M | Sep 21, 2022 | Direct | F1, F7 |
| transaction | MRNA | Common Stock | Options Exercise | $39.6K | +40K | +0.74% | $0.99* | 5.45M | Sep 22, 2022 | Direct | F1 |
| transaction | MRNA | Common Stock | Sale | -$1.9M | -15.3K | -0.28% | $124.21 | 5.44M | Sep 22, 2022 | Direct | F1, F8 |
| transaction | MRNA | Common Stock | Sale | -$3.03M | -24.3K | -0.45% | $125.08 | 5.41M | Sep 22, 2022 | Direct | F1, F9 |
| transaction | MRNA | Common Stock | Sale | -$50.4K | -400 | -0.01% | $125.88 | 5.41M | Sep 22, 2022 | Direct | F1, F10 |
| transaction | MRNA | Common Stock | Sale | -$1.24M | -10K | -0.15% | $124.20 | 6.7M | Sep 22, 2022 | See Footnote | F11, F12 |
| holding | MRNA | Common Stock | 9.05M | Sep 21, 2022 | See Footnote | F13 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MRNA | Stock Option (Right to Buy) | Options Exercise | $0 | -40K | -1.24% | $0.00 | 3.19M | Sep 21, 2022 | Common Stock | 40K | $0.99 | Direct | F1, F14 |
| transaction | MRNA | Stock Option (Right to Buy) | Options Exercise | $0 | -40K | -1.26% | $0.00 | 3.15M | Sep 22, 2022 | Common Stock | 40K | $0.99 | Direct | F1, F14 |
| Id | Content |
|---|---|
| F1 | The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022. |
| F2 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $125.88 to $126.64. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F3 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $127.03 to $128.02. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F4 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $128.06 to $129.06. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F5 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $129.07 to $130.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F6 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $130.08 to $131.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F7 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $131.32 to $131.55. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F8 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $123.75 to $124.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F9 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $124.76 to $125.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F10 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $125.80 to $125.97. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F11 | This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on September 16, 2019. |
| F12 | These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. |
| F13 | These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. |
| F14 | This option is fully vested and exercisable. |